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SUMMARY – Luminal B (HER2 negative) subtype is the most diversiform type of breast can-
cers, with a high Ki-67 proliferation index (>20%) or/and low progesterone (PR; <20%) with various 
intensity and distribution of hormone receptors. Considerable diff erence has also been noticed in 
disease outcome, wherefore there is the need for a more detailed classifi cation of this tumor subtype. 
Th e clinical and pathologic parameters of 147 luminal B (HER2 negative) breast cancers were exam-
ined. Th e expression of hormone receptors in correlation with other prognostic factors and disease 
outcome was analyzed by Kaplan-Meier curves and multivariate Cox regression analysis. Th e Kaplan-
Mayer analysis showed that low positivity of estrogen (ER) and PR receptors in tumors was associ-
ated with a signifi cantly worse disease outcome (overall survival (ER), p=0.020; disease free survival 
(ER), p=0.019; overall survival (PR), p=0.026; disease free survival (PR), p=0.038)), unlike Ki-67, 
which did not show a statistically signifi cant connection (overall survival, p=0.343; disease free sur-
vival, p=0.322). Th e intensity of receptor staining and Ki-67 relative to other histopathologic prognos-
tic factors showed a statistically signifi cant correlation solely with histologic grade of tumor. By using 
the Cox regression model, PR proved to be an independent prognostic factor for overall survival 
(p=0.004) and disease free survival (p=0.029). Th e luminal B (HER2 negative) breast cancer with low 
expression of hormone receptors, independent of the Ki-67 proliferation index, and in correlation with 
a higher histologic grade, could be a unique subtype of cancer.
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Introduction
Breast cancer is still the most common malignant 
tumor in women and a signifi cant healthcare issue1. As 
it is well known, breast cancer is a heterogeneous dis-
ease2, the course and outcome of which is assessed by 
prognostic parameters including tumor size, histologic 
grade, histologic subtype and lymph node involve-
ment, along with estrogen (ER) and progesterone 
(PR) receptor expression3. Diff erent breast cancer clas-
sifi cations use these parameters to most accurately as-
sess disease outcome and modify oncologic therapy by 
the more individualistic approach. However, the most 
recent molecular research has attributed a new classifi -
cation that divides breast cancer into 4 subtypes (lumi-
nal A, luminal B, HER2 positive and basal-like). Th is 
classifi cation was accepted at the 12th St. Gallen Inter-
national Breast Cancer Conference held in 2011, and 
it is now widely used. Th e classifi cation itself is based 
primarily on the expression of single gene groups (ex-
pression of ER and PR in luminal subtypes or HER2 
and proliferation gene groups in basal-like and HER2 
positive subtypes), although the fi nancially more ac-
ceptable and accessible immunohistochemical inter-
pretation of ER, PR and HER2 receptors, as well as 
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Ki-67 proliferation index, which are needed to place 
the tumor in a precise group, has been accepted as an 
appropriate replacement method. By using the immu-
nohistochemistry method, breast cancers are also clas-
sifi ed into four groups: luminal A, luminal B, HER2 
positive and triple negative4.
Th e hormone positive tumors fall into the category 
of luminal A or luminal B subtypes, mostly dependent 
on the Ki-67 proliferation index, which is higher in 
the luminal B subtype. At the 13th St. Gallen Consen-
sus Conference held in 2013, a cut-off  value of 20% 
was proposed for Ki-67; using it, tumors with higher 
values are placed into luminal B subtype, as well as those 
tumors that have weaker expression (less than 20%) of 
ER or PR, in addition to tumors that have one nega-
tive receptor5. Luminal A subtype cancer have better 
and more favorable outcome and it is also well known 
that they have better response to hormonal therapy 
than luminal B cancers; in fact, it is the most heteroge-
neous subtype of breast cancer. Th e Ki-67 proliferation 
index has a considerable range in this subtype of can-
cer (20%-100%), but even more diversiform is the 
positivity span of hormones that can diff er from only 
focal mild positivity in a single tumor cell to diff use 
intensive positivity in all tumor cells6. Given that the 
heterogeneity of this tumor subtype is also refl ected in 
disease outcome7, the question arises whether the lu-
minal B (HER2 negative) population with lower Ki-
67 proliferation index and more intensive and diff use 
positivity of receptors is the one that is more similar to 
the luminal A subtype (with better prognosis), both by 
response to hormone therapy and less aggressive be-
havior, and whether this group of luminal B (HER2 
negative) cancers can be divided into subgroups of 
those with better and worse outcomes (by immunohis-
tochemical assessment of ER, PR and Ki-67 and in 
correlation with the common prognostic parameters).
Unlike other prognostic parameters (lymph node 
status, tumor grade, lymphovascular invasion), the role 
of which in the assessment of tumor behavior and thus 
the appropriate therapeutic guideline is relatively dis-
tinct, the level of tumor positivity needed for inclusion 
of endocrine therapy in ER positive tumors is still 
partly unclear. Should tumors with high positivity 
stains, with proved better outcome receive adjuvant 
chemotherapy, is also a question that should be an-
swered8.
Th is study included 147 luminal B (HER2 nega-
tive) breast cancers that were determined by immuno-
histochemical analysis of ER, PR, HER2 and Ki-67 
proliferation index, in order to establish the connec-
tion of usual prognostic parameters with hormone re-
ceptor staining intensity and percentage of positive 
cells, along with Ki-67 proliferation index, in correla-
tion with clinical outcome (overall survival (OS) and 
disease free survival (DFS)).
Material and Methods
A retrospective study included 147 invasive breast 
cancers from patients having undergone surgical tu-
mor resection in 2006, 2007 and 2008 at the Depart-
ment of Surgery, Osijek University Hospital Centre in 
Osijek. Archival materials from the Department of 
Pathology and Forensic Medicine, Osijek University 
Hospital Centre, were used to record and re-evaluate 
the histopathologic data. Using a four-marker immu-
nopanel (ER, PR, HER2 and Ki-67), luminal B 
(HER2 negative) specimens were isolated, according 
to the 2011 St. Gallen International Expert Consen-
sus criteria, as revised at the 2013 and 2015 Confer-
ences (Ki-67 ≥20% and/or PR <20%).
Th e immunohistochemical analysis was performed 
on formalin fi xed, paraffi  n embedded tissue on a Ven-
tana automated slide stainer. Th e following rabbit 
monoclonal primary antibodies were used: Confi rm 
anti-estrogen receptor (ER) (clone SP1), Confi rm 
anti-progesterone receptor (PR) (clone 1E2), Confi rm 
anti-Ki-67 (clone 30-9) and Pathwayanti HER-2/neu 
(clone 4B5). Th ese antibodies were optimally diluted 
for use with the Ventana ultra VIEW Universal DAB 
detection kit. Th e slides were evaluated under a light 
microscope by two independent pathologists.
To determine the ER and PR receptor status, scor-
ing by the method proposed by Allred et al. was used9. 
Percentage of positive cells (0 = no positive cells; 
1=<1%; 2=1%-10%; 3=11%-33%; 4=34%-66%; and 
5=>67% of positive cells) and intensity (0 = none; 1 = 
weak; 2 = intermediate; and 3 = strong intensity) were 
added, yielding a score of 0-8. HER-2 immunostain-
ing was graded as follows: 0, 1+, 2+, and 3+. Intensity 
scores of 0 or 1+ were designated as negative expres-
sion and 3+ as positive expression for HER2/neu. Th e 
2+ score was further subjected to silver-enhanced in 
situ hybridization (SISH) analysis.
Th e Ki-67 proliferation index was measured ac-
cording to the recommendations from the Interna-
tional Ki-67 in the Breast Cancer Working Group10.
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Histologic classifi cation of tumor specimens was 
based on the World Health Organization criteria11, 
and tumors were graded according to the Scarff -
Bloom Richardson classifi cation as modifi ed by Elston 
and Ellis12. Tumor size was divided into four groups 
(>0.5≤1.0 cm; >1≤2 cm; >2≤5 cm; and >5 cm) and 
lymph node status into four groups, as follows: N0 
(negative lymph node); N1 (1-3 positive nodes); N2 
(4-9 positive nodes); and N3 (>10 positive nodes).
Demographic and clinical features of the patients 
were obtained from hospital charts. Patients having a 
metastatic disease at presentation were excluded. DFS 
was determined as the period without locoregional or 
distant recurrence. Locoregional recurrence was de-
fi ned as a tumor occurring at the resection site and 
distant recurrence was defi ned as a tumor outside the 
site of resection including the liver, adrenals, lungs or 
bones. Th e recurrence was diagnosed by radiologic im-
age or biopsy.
Statistical analysis
Th e data collected were statistically analyzed using 
the MedCalc Statistical Software version 16.4.2 
(MedCalc Software bvba, Ostend, Belgium; https://
www.medcalc.org; 2016). Th e survival time was calcu-
lated in months starting from the date of the surgery. 
Fisher exact test for categorical data was used to 
 analyze any relationship between the clinical and 
 histopathologic factors. Survival analysis of censored 
data was performed using the Kaplan-Meier method. 
Th e log-rank test was used to compare survival data 
curves. Th e univariate and multivariate stepwise pro-
portional-hazard analysis (Cox model) was performed 
to identify the variables signifi cantly associated with 
survival. Cut-off  values were defi ned using the ROC 
analysis.
Categorical data were expressed as absolute and 
relative frequencies, whereas numerical data and scores 
were expressed with median and interquartile range. 
Th e level of statistical signifi cance was set at p<0.05.
Results
In the study sample, the median age was 62 (53-
70), range 33 to 83 years. Most of the tumors, 102 
(69.38%) were diagnosed as not otherwise specifi ed 
(NOS), whereas 22 (14.96%) were invasive lobular 
cancers and 23 (15.66%) were pooled as ‘other types’ in 
this study. As many as 128 (87.00%) cases were well or 
moderately diff erentiated (grade 1 and 2), and only 19 
(13.00%) were poorly diff erentiated (grade 3). Lymph 
node metastases were recorded in 55.10% of study pa-
tients (Table 1). Signifi cantly, most of the tumors were 
>2≤5 cm in size (Table 1).
Th e median follow up period was 80.7 months 
with the interquartile range of 35.7-103.5 months and 
total range of 1.9-128.2 months. During the study pe-
riod, 53 (36.1%) patients died. Recurrences were re-
ported in 45 (30.7%) patients, as follows: local recur-
rences in 7 (4.8%) and distant recurrences in 38 
(25.9%) cases.
In this group of patients, there were no ER nega-
tive tumors, 9 tumors were PR negative, and another 8 
tumors had less than 20% of PR positive staining cells. 
All of these tumors had Ki-67 proliferation index 
above 20%.
Th e ER and PR scores, as well as Ki-67 prolifera-
tion index were signifi cantly correlated with tumor 
grade (ER p=0.037; PR p=0.008; and Ki-67 p<0.001). 
However, ER and PR scores along with Ki-67 prolif-
eration index were not associated with other parame-
Table 1. Patient and tumor characteristics
n (%)
Histology














N1 (1-3) 34 (23.1)
N2 (4-9) 30 (20.4)
N3 (>10) 17 (11.6)
Total 147 (100.0)
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Table 2. Estrogen correlation with other parameters
ER score 3-5 6 7 8 p*
Histology
NOS 21 (67.7) 27 (90.0) 28 (65.1) 26 (60.5)
0.184lobular 5 (16.1) 2 (6.7) 7 (16.3) 8 (18.6)
others 5 (16.1) 1 (3.3) 8 (18.6) 9 (20.9)
Tumor size (cm)
>0.5≤1.0 4 (12.9) 2 (6.7) 3 (7.0) 8 (18.6)
0.291
>1≤2 12 (38.7) 6 (20.0) 17 (39.5) 15 (34.9)
>2≤5 13 (41.9) 18 (60.0) 18 (41.9) 19 (44.2)
>5 2 (6.5) 4 (13.3) 5 (11.6) 1 (2.3)
Grade
1 12 (38.7) 11 (36.7) 18 (41.9) 23 (53.5)
0.0372 13 (41.9) 11 (36.7) 24 (55.8) 16 (37.2)
3 6 (19.4) 8 (26.7) 1 (2.3) 4 (9.3)
Lymph node status
N0 14 (45.2) 9 (30.0) 18 (41.9) 25 (58.1)
0.116
N1 (1-3) 8 (25.8) 7 (23.3) 13 (30.2) 6 (14.0)
N2 (4-9) 8 (25.8) 8 (26.7) 5 (11.6) 9 (20.9)
N3 (>10) 1 (3.2) 6 (20.0) 7 (16.3) 3 (7.0)
Total 31 (100.0) 30 (100.0) 43 (100.0) 43 (100.0)
*Fisher exact test; ER = estrogen; NOS = not otherwise specifi ed
Table 3. Progesterone correlation with other parameters
PR score 0 2-5 6 7 8 p*
Histology
NOS 7 (77.8) 33 (78.6) 16 (69.6) 24 (66.7) 22 (59.5)
0.593lobular 1 (11.1) 4 (9.5) 5 (21.7) 4 (11.1) 8 (21.6)
others 1 (11.1) 5 (11.9) 2 (8.7) 8 (22.2) 7 (18.9)
Tumor size (cm)
>0.5≤1.0 2 (22.2) 4 (9.5) 3 (13.0) 3 (8.3) 5 (13.5)
0.543
>1≤2 3 (33.3) 17 (40.5) 6 (26.1) 10 (27.8) 14 (37.8)
>2≤5 2 (22.2) 20 (47.6) 12 (52.2) 20 (55.6) 14 (37.8)
>5 2 (22.2) 1 (2.4) 2 (8.7) 3 (8.3) 4 (10.8)
Grade
1 3 (33.3) 16 (38.1) 13 (56.5) 11 (30.6) 21 (56.8)
0.0082 3 (33.3) 21 (50.0) 4 (17.4) 21 (58.3) 15 (40.5)
3 3 (33.3) 5 (11.9) 6 (26.1) 4 (11.1) 1 (2.7)
Lymph node status
N0 4 (44.4) 17 (40.5) 8 (34.8) 15 (41.7) 22 (59.5)
0.832
N1 (1-3) 1 (11.1) 10 (23.8) 7 (30.4) 9 (25.0) 7 (18.9)
N2 (4-9) 3 (33.3) 8 (19.0) 5 (21.7) 8 (22.2) 6 (16.2)
N3 (>10) 1 (11.1) 7 (16.7) 3 (13.0) 4 (11.1) 2 (5.4)
Total 9 (100.0) 42 (100.0) 23 (100.0) 36 (100.0) 37 (100.0)
*Fisher exact test; PR = progesterone; NOS = not otherwise specifi ed
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ters such as lymph node metastasis, tumor size and 
histologic subtype (Tables 2-4).
On the Kaplan-Meier analysis, ER and PR scores 
were signifi cantly associated with longer DFS (ER 
p=0.019; and PR p=0.038) and OS (ER p=0.020; and 
PR p=0.026); there was no statistically signifi cant as-
sociation of Ki-67 with OS (p=0.343) or DFS 
(p=0.322) (Fig. 1).
Univariate and multivariate Cox analysis was per-
formed, including age, ER/PR score and Ki-67 prolif-
eration index (Tables 5 and 6). For OS and DFS, PR 
was found to be a statistically signifi cant independent 
prognostic parameter (OS p=0.004; and DFS p=0.029), 
while age was statistically correlated with OS 
(p<0.001). In this analysis, neither ER nor Ki-67 pro-
liferation index seemed to have an independent role in 
OS and DFS.
Discussion
Luminal B (HER2 negative) subtype of breast 
cancer, as defi ned at the last 2015 St. Gallen Consen-
sus in Vienna 20155, is the most heterogeneous type of 
breast cancer compared to other subtypes determined 
by molecular gene profi ling. As it is known, apart from 
previously listed histopathologic and molecular char-
Table 4. Ki-67 correlation with other parameters
Ki-67 
index (%) 
20-30 31-40 41-100 p*
Histology
NOS 33 (60.0) 34 (75.6) 35 (74.5)
0.405lobular 10 (18.2) 5 (11.1) 7 (14.9)
others 12 (21.8) 6 (13.3) 5 (10.6)
Tumor size (cm)
>0.5≤1.0 10 (18.2) 4 (8.9) 3 (6.4)
0.421
>1≤2 19 (34.5) 18 (40.0) 13 (27.7)
>2≤5 22 (40.0) 20 (44.4) 26 (55.3)
>5 4 (7.3) 3 (6.7) 5 (10.6)
Grade
1 32 (58.2) 21 (46.7) 11 (23.4)
<0.0012 22 (40.0) 19 (42.2) 23 (48.9)
3 1 (1.8) 5 (11.1) 13 (27.7)
Lymph node status
N0 31 (56.4) 19 (42.2) 16 (34.0)
0.413
N1 (1-3) 9 (16.4) 12 (26.7) 13 (27.7)
N2 (4-9) 10 (18.2) 8 (17.8) 12 (25.5)
N3 (>10) 5 (9.1) 6 (13.3) 6 (12.8)
Total 55 (100.0) 45 (100.0) 47 (100.0)
*Fisher exact test; NOS = not otherwise specifi ed
Fig. 1. Kaplan-Meier survival analysis of estrogen (ER), progesterone (PR) and Ki-67.
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acteristics, certain clinical characteristics are featured 
in this group, including worse relapse free survival, an 
increased risk of early relapse, predisposition to bone 
and pleural relapse, relative insensitivity to endocrine 
therapy (in comparison to luminal A subtype) and 
relative insensitivity to chemotherapy (in comparison 
to basal-like subtype)8.
Sørlie et al. showed in their research that breast 
cancer could be divided into certain groups based on 
molecular profi ling of genes, and they introduced a 
new concept of luminal C carcinoma as a distinct sub-
type that is linked with the worst outcome13. Th e ex-
pression of numerous genes, otherwise characteristic 
of basal-like and HER2 positive cancers, has been no-
ticed in this subtype of cancer, in addition to ER and 
PR expression.
Recent researches of luminal B cancers, which 
show weaker intensity on hormone receptor staining 
or negative staining for one of the hormones, are also 
of great interest. Th us, Gloyeske et al. proved in their 
work that luminal B type with low ER intensity re-
sembled the basal-like cancer morphologically, as well 
as by the degree of chemotherapy response14. Park et al. 
presented a group of cancers that were negative for one 
of the hormone receptors as a subgroup of luminal B 
(HER2 negative) cancers with worse prognosis15. It 
has also been demonstrated that luminal B subtype 
with low expression of ER has poorer complete patho-
logic response to neoadjuvant therapy, as compared 
with cancers with high expression. Th e response to 
neoadjuvant therapy is very much alike that of ER 
negative tumors, however, only in the group of luminal 
B HER2 negative subtype16.
Dvorkin-Gheva and Hassell found, by molecular 
profi ling of genes in diverse breast cancers, that there 
were 35% of those that could not be placed in any of 
Table 5. Univariate and multivariate prognostic analysis of 147 patients according to desease free survival
Characteristic
Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p*
Age (yrs)
<66†
1.259 0.663-2.391 0.482 1.448 0.748-2.801 0.272
ER (score)
≤7†
0.556 0.256-1.208 0.138 0.594 0.270-1.306 0.195
PR (score)
≤7†
0.257 0.091-0.723 0.010 0.314 0.111-0.892 0.029
Ki-67(%)
>26†
0.522 0.248-1.099 0.087 0.539 0.253-1.150 0.110
*COX regression model; †cut off  value determined by ROC analysis; HR = hazard ratio; 95% CI = 95% confi dence interval; 
ER = estrogen; PR = progesterone
Table 6. Univariate and multivariate prognostic analysis of 147 patients according to overall survival
Characteristic
Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p*
Age (yrs)
<69†
3.246 1.887-5.584 <0.001 3.868 2.169-6.895 <0.001
ER (score)
≤5†
0.485 0.219-1.075 0.075 0.878 0.387-1.992 0.755
PR (score)
≤7†
0.299 0.128-0.700 0.005 0.279 0.117-0.666 0.004
Ki-67 (%)
>31†
0.604 0.339-1.076 0.087 0.604 0.336-1.084 0.091
*COX regression model; †cut off  value determined by ROC analysis; HR = hazard ratio; 95% CI = 95% confi dence interval; 
ER = estrogen; PR = progesterone
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the fi ve defi nitive subtypes of tumors, and argued that 
there was a specifi c category of luminal-like tumors 
characterized by high expression of ER and PR genes 
in 95% of cases17. Th is subtype distinctly diff ers from 
the aforementioned luminal C subtype and, even 
though they have a low degree of HER2 amplifi cation, 
the transcription profi les  of genes similar to luminal A 
and B tumors were established in about 25% of cases. 
Clinical follow up established that this group of pa-
tients had better outcome than the basal-like subtype, 
although worse than the luminal A subtype. In daily 
routine, a large proportion of these tumors are certain-
ly categorized using immunohistochemical methods 
as the luminal B (HER2 negative) subtype, and pos-
sibly these being the ones that show lower hormone 
expression rate along with poorer prognosis and dis-
ease outcome.
Th rough Kaplan-Meier curves, a statistically sig-
nifi cant connection was found between lower ER and 
PR expression rate and worse disease outcome (OS 
and DFS), which is in accordance with recent re-
searches and favors the distinct subtype of luminal B 
(HER2 negative) cancers that express lower hormone 
positivity and have a more aggressive course.
In their meta-analysis, the Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) proved 
that tamoxifen improved relapse free survival in ER 
positive tumors, independently of the PR status. On 
the other hand, Cancello et al. showed an interconnec-
tion of the negative PR receptors with a higher risk of 
disease relapse18. Furthermore, Zong et al. showed that 
the luminal B (HER2 negative) tumors had an in-
creased risk of disease relapse when PR receptors were 
negative, even with well-conducted endocrine and ad-
juvant chemotherapies19. Using multivariate Cox re-
gression analysis, in this study, a statistically signifi cant 
impact of PR intensity on OS and DFS was estab-
lished, implying the importance of negative or low 
positive PR expression as the isolated criterion in the 
assessment of disease outcome.
Th e American Society of Clinical Oncology and the 
College of American Pathologists (ASCO/CAP) have 
proposed that ER status should be considered positive if 
1% or more tumor cells express nuclear positivity by im-
munohistochemical staining. Additionally, they suggest 
semiquantitative evaluation of immunohistochemical 
staining results (H-score or Allred method)20. It is well 
known that hormone therapy is applied in tumors with 
positive hormone receptors, however, only some pa-
tients with positive hormone receptors receive addition-
al chemotherapy, mostly depending on the tumor bio-
logical characteristics21. Recent studies additionally 
demonstrate clinical importance of semiquantitative 
evaluation of hormone receptors, arguing that tumors 
with lower expression of hormone receptors can be, in 
addition to other parameters, a criterion for the intro-
duction of chemotherapy22.
From this, it can be concluded that hormone recep-
tor staining and percentage of positive staining cells is 
an important prognostic parameter in luminal B 
(HER2 negative) breast cancer. Furthermore, it can be 
concluded that the groups with lower intensity of pos-
itive hormone receptors, as well as those with one neg-
ative receptor can be placed into a unique group of 
luminal B (HER2 negative) breast cancer, based on 
the proven worse disease outcome and independently 
of most of the usual prognostic parameters.
Th e Ki-67 proliferation index is acknowledged as 
being important for distinction between luminal A 
and luminal B subtypes of cancer, in addition to esti-
mation of a more aggressive disease course. In the 
given study group, all tumors had Ki-67 value >20%. 
Th ere were 17 tumors that had negative or low (<20%) 
percentage of PR positive cells, yet all of these tumors 
had high Ki-67 proliferation index, and nevertheless 
had to be placed in the luminal B subtype. However, 
the Ki-67 proliferation index value had no impact on 
disease outcome in the presented group of patients and 
did not appear as a relevant factor regarding disease 
outcome.
Th e present study showed, by correlation analysis 
of ER and PR values and Ki-67 index with other clin-
ical and pathologic parameters, a statistically signifi -
cant correlation solely with tumor grade. Tumors with 
lower ER and PR intensity and higher Ki-67 prolif-
eration activity were of a statistically signifi cantly 
higher grade. Considering these results, it is concluded 
that in the group of tumors with weaker hormone pos-
itivity and those with higher Ki-67 proliferation activ-
ity, the histologic grade of the tumor can be a signifi -
cant parameter when more aggressive oncologic thera-
py is to be determined (in regard to other parameters 
including tumor size or axillary lymph node involve-
ment).
Accordingly, besides molecular analyses and deli-
cate gene profi ling (which is unquestionably becoming 
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necessary in the near future for malignant tumor diag-
nosis and analysis), the basic pathologic examination 
of tumor tissue remains a highly useful method, along 
with precise assessment of the parameters (percentage 
of tubule formation, degree of nuclear pleomorphism 
and accurate mitotic count) needed for tumor grading.
Finally, we conclude that the luminal B (HER2 
negative) breast cancers with low hormone expression 
and independent of the Ki-67 proliferation index, 
might be a separate tumor group, and thus candidates 
for a more aggressive oncologic therapy. Independent-
ly of the new, modern methods of gene profi ling, the 
old practice of histopathologic assessment of tumor 
grade and hormone receptor intensity, as well as the 
semiquantitative evaluation of ER and PR expression 
in tumor tissue are still essential in daily routine.
For better individual modifi cation of oncologic 
therapy, the luminal B (HER2 negative) breast cancers 
should be additionally researched, and receptor inten-
sity in this group of cancers could be an additional fac-
tor for adjuvant chemotherapy administration.
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Sažetak
PROGNOSTIČKI UTJECAJ NISKOG POZITIVITETA 
ESTROGENIH I PROGESTERONSKIH RECEPTORA 
U LUMINALNIM B (HER2 NEGATIVNIM) KARCINOMIMA DOJKE
J. Rajc, I. Fröhlich, M. Mrčela, I. Tomaš i J. Flam
Luminalni B (HER 2 negativni) karcinomi dojke najheterogenija su podskupina s velikim rasponom proliferacijskog 
indeksa Ki-67 kao i intenziteta te raspodjele hormonskih receptora unuatar tumorskih stanica. Također je zamjetna različi-
tost u kliničkom ishodu bolesti, zbog čega se ukazuje potreba za detaljnijom subtipizacijom ove skupine tumora. Izdvojeno 
je 147 luminalnih B HER2 negativih karcinoma, a ispitani su kliničko-patološki parametri u korelaciji s intenzitetom hor-
monskih receptora (estrogen (ER) i progesteron (PR)) kao i Ki-67 u odnosu na sveukupno preživljenje te preživljenje bez 
povrata bolesti. Unutar ispitivanih kliničko patoloških parametara slabiji intenzitet hormonskih receptora kao i viši Ki-67 bili 
su statistički značajno povezani samo s gradusom tumora. Kaplan-Meierovom analizom ustanovljena je statistički značajna 
povezanost slabog intenziteta ER i PR s preživljenjem (sveukupno preživljenje (ER), p=0,020; preživljenje bez povrata bole-
sti (ER), p=0,019; sveukupno preživljenje (PR), p=0,026; preživljenje bez povrata bolesti (PR), p=0,038)), za razliku od Ki-67 
vrijednosti kojega nisu bile statistički značajno povezane s preživljenjem (sveukupno preživljenje, p=0,343; preživljenje bez 
povrata bolesti, p=0,322). Coxovom regresijskom analizom PR se pokazao kao statistički značajan neovisni parametar 
 povezan sa sveukupnim preživljenjem (p=0,004) i preživljenjem bez povrata bolesti (p=0,029). Ovi rezultati pokazuju da bi 
podskupina luminalnih B HER2 negativnih karcinoma dojke s niskim intenzitetom hormonskih receptora, neovisno o 
 proliferacijskom indeksu Ki-67, a u korelaciji s histološkim gradusom tumora mogla biti zaseban podtip karcinoma dojke.
Ključne riječi: Dojka, tumori; Receptori, estrogen; Receptori, progesteron; Preživljavanje bez bolesti; Hrvatska
